SB-271046A
SIGMA/S5326 - ≥98% (HPLC)
Synonym: 5-
CAS Number: 209481-24-3
Empirical Formula (Hill Notation): C20H22ClN3O3S2 · HCl
Molecular Weight: 488.45
MDL Number: MFCD10565914
Linear Formula: C20H22ClN3O3S2 · HCl
Product Type: Chemical
| assay | ≥98% (HPLC) |
| form | powder |
| InChI | 1S/C20H22ClN3O3S2.ClH/c1- |
| InChI key | RMXZRJYGJMSDQK-UHFFFAOYSA |
| originator | GlaxoSmithKline |
| Quality Level | 100  |
| SMILES string | Cl.COc1ccc(NS(=O)(=O)c2sc |
| solubility | DMSO: >20 mg/mL |
| storage temp. | 2-8°C |
| Biochem/physiol Actions: | SB-271046A is a 5-HT6 receptor antagonist. |
| Biochem/physiol Actions: | The first potent and selective 5-HT6 antagonist. Training in cognitive tasks, as well as administration SB-271046, induces an increase in pERK1/2 and pCREB1 levels, while CREB2 levels are significantly reduced; cognition-enhancing properties of SB-271046 are attributed to the effect on pERK1/2, not pCREB1/2. SB-271046 reverses MK-801-induced, but not scopolamine-induced, learning impairments. However, with coadministration of galanthamine, both types of learning impairments were ameliorated. |
| Features and Benefits: | This compound was developed by GlaxoSmithKline . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 5, 25 mg in glass bottle |
| RIDADR | NONH for all modes of transport |
| WGK Germany | nwg |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |